Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aripiprazole maintenance in adolescent schizophrenia or bipolar I
NCT01122927Phase 3Terminated
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jul 2010
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 3 trial of aripiprazole in schizophrenia, bipolar I disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Jul 2010; status: terminated.
02
Drugs
aripiprazole
03
Conditions
schizophreniabipolar I disorder
Beyond the preview
Go deeper on NCT01122927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01122927.